Tay Sachs Clinical Trials 2024

What are the top hospitals conducting Tay sachs research?

In the quest to find effective treatments and breakthroughs for Tay-Sachs disease, several top hospitals are leading the charge. One such institution is Mayo Clinic in Rochester, which currently has one active clinical trial dedicated specifically to Tay-Sachs. While their overall contribution may seem modest with two recorded trials thus far, it's important to note that they only began exploring this rare neurological condition recently, starting their first trial as recent as 2022.

Another notable hospital making strides in Tay-Sachs research is Queen's University/Kingston Health Sciences Centre located in Kingston. With one ongoing clinical trial and a single previous trial under their belt since embarking on this journey in 2021, they have quickly established themselves as a key player within the field.

Meanwhile, Massachusetts General Hospital's Center for Rare Neurological Diseases in Boston also holds promise. They too are conducting an active Tay-Sachs trial alongside their initial investigation initiated just last year—both aimed at unraveling new insights into this devastating disorder.

The University of Massachusetts Medical Health Center situated in Worcester likewise demonstrates its commitment to finding answers for those affected by Tay-Sachs through its current involvement in an active clinical trial and prior participation dating back to 2021.

Last but not least, nestled among these esteemed institutions is the Ataxia Center and HD Center of Excellence located within UCLA Med Plaza in Los Angeles. Though geographically distinct from the other hospitals mentioned above, they share a common purpose—to combat rare diseases like Tay-Sachs. Having commenced their first recorded trial focusing on this particular ailment back in 2020, they continue making progress with another ongoing study today.

These highly regarded medical centers represent beacons of hope for individuals impacted by Tay-Sachs disease worldwide. Despite being relatively new targets of exploration compared to more well-known conditions or diseases; researchers across these facilities demonstrate unwavering dedication towards understanding this rare neurologic illness better - every small step taken bringing us closer to a brighter, healthier future for those affected by Tay-Sachs.

Which are the best cities for Tay sachs clinical trials?

When it comes to Tay-Sachs clinical trials, several cities offer opportunities for individuals seeking innovative treatments. Boston, Massachusetts leads the way with 2 active trials focusing on AXO-AAV-GM2 Starting Dose and venglustat GZ402671. Rochester, Minnesota also hosts a trial investigating AZ-3102 (Dose 1), while Kingston, Ontario explores the potential of TSHA-101. Additionally, Worcester, Massachusetts conducts a study on AXO-AAV-GM2 Starting Dose, and Los Angeles, California investigates venglustat GZ402671. These cities serve as hubs for cutting-edge research in Tay-Sachs disease treatment options and provide hope for those affected by this rare genetic disorder.

Which are the top treatments for Tay sachs being explored in clinical trials?

Exciting developments are underway in clinical trials exploring potential treatments for Tay-Sachs disease. Among the top contenders are:

• AZ-3102 (Dose 1): The first active trial for this treatment, listed in 2023.
• TSHA-101: A promising candidate with one active trial and first listed in 2021.
• AXO-AAV-GM2 Starting Dose: Another hopeful option currently being tested, also introduced in 2021.
• Venglustat GZ402671: A newer entry into the field, with one active trial since its listing in 2020.
• DUOC-01: This treatment has been making strides since its introduction back in 2014.

These exciting clinical trials hold promise for advancing the fight against Tay-Sachs disease and bringing hope to affected individuals and their families.

What are the most recent clinical trials for Tay sachs?

Recent clinical trials offer hope for individuals affected by Tay-Sachs disease, a devastating genetic disorder. One such trial is examining the efficacy of AZ-3102 in treating Tay-Sachs patients. This Phase 2 study, which became available on 4/24/2023, aims to assess the potential benefits and safety profile of this experimental treatment. Another promising trial involves TSHA-101, currently in both Phase 1 and Phase 2 stages since becoming available on 3/12/2021. AXO-AAV-GM2 Starting Dose entered its Phase 1 stage on 1/15/2021 as another avenue for exploring potential treatments for Tay-Sachs disease. These studies represent crucial steps towards finding effective interventions that can alleviate suffering caused by this rare condition.

What Tay sachs clinical trials were recently completed?

A recent milestone in the search for effective treatments against Tay-Sachs disease was achieved with the completion of a clinical trial sponsored by IntraBio Inc. The trial investigated IB1001 as a potential therapy and concluded in June 2019. This significant achievement underscores ongoing efforts to combat this devastating genetic disorder, offering hope to patients and their families affected by Tay-Sachs.